| Species |
Human |
| Protein Construction |
TrkA (Ala34-Pro407)
Accession # P04629 |
|
| Purity |
> 95% as analyzed by SDS-PAGE |
| Endotoxin Level |
< 0.2 EU/μg of protein by gel clotting method |
| Biological Activity |
ED50 < 1.0 μg/ml, measured in a neutralization assay in the presence of 10.0 ng/ml human β-NGF using TF-1 Cells. |
| Expression System |
HEK 293 |
| Apparent Molecular Weight |
65~85 kDa, on SDS-PAGE under reducing conditions. |
| Formulation |
Lyophilized after extensive dialysis against PBS. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH?O or PBS up to 100 μg/ml. |
| Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |
| Target Background |
Tyrosine kinase receptor A (Trk-A) is a member of the neurotrophic tyrosine kinase receptor family which includes three members: Trk-A, Trk-B and Trk-C. Trk-A is involved in the development and maturation of the central and peripheral nervous systems through regulation of proliferation, differentiation and survival of sympathetic neurons. |
| Synonyms |
NTRK1; MTC; TRK; TRK1; TRKA; Trk-A; p140-TrkA; neurotrophic receptor tyrosine kinase 1 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
